Latest News

Treat-and-extend with ranibizumab comparable to monthly treatment for wet AMD

Peter Kertes
VANCOUVER, British Columbia — A 24-month treat-and-extend analysis trial with ranibizumab for patients with neovascular age-related macular degeneration showed statistically significant improvements in best corrected visual acuity at 12 months compared with a monthly dosing regimen, according to a speaker here.
“Treat-and-extend induces significantly higher visual acuity improvement at 12 months compared to monthly administration and comparable improvement at 24 months, but with fewer visits and fewer injections,” Peter Kertes, MD, FRCS(C), said at the American

Source link

Related posts

Zombie Science: Can They Ever Be Real?


A Story of Innovative Molecules: From Machines to Cyclic Compounds


Do Mindfulness Apps Really Help Your Health?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy